Sanofi (SNY) Stock News: October 2026

Sanofi lifted its full-year guidance for the second time this year after third-quarter sales beat expectations, driven by Dupixent and recent launches. Dupixent sales rose 35% at constant currency to 5.69 billion euros, nearly 40% of total revenue. Core EPS climbed 20% at constant currency to 3.55 euros, above the 2.81-euro consensus. Net sales rose 14% at constant currency to 14.44 billion euros, ahead of the 13.25-billion-euro forecast. CEO Belen Garijo said M&A will be critical to complement the turnaround, targeting late-stage or marketed assets in immunology, rare diseases, and vaccines. The company is preparing for Dupixent's patent expiration in the early 2030s.

Sanofi reported strong Q3 results and raised full-year guidance. J.P. Morgan says Dupixent drove half the sales beat; vaccines also beat consensus. New guidance could drive 3-5% consensus upgrades.